Analysis of the low levels of catecholamines and metabolites in tissue and biological fluids has necessitated the use of highly sensitive analytical techniques. Earlier procedures utilizing radioenzymatic and immunological assays, gas chromatography or fluorimetry have generally been superseded by highly sensitive and selective chromatographic methods utilizing electrochemical or fluorimetric detection. The development of high-performance liquid chromatography (HPLC) methods for the measurement of plasma metadrenalines and the combination of HPLC with tandem mass spectrometry provides additional procedures with minimum interference from drugs and drug metabolites. This review summarizes the methodology currently available for the measurement of catecholamines and metabolites in plasma and urine, the influence of sample collection protocols and the clinical application of the methods for the biochemical detection of catecholamine-secreting tumours.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1258/000456304322664663 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comprehensive, Quantitative Analysis of SRM 1950: the NIST Human Plasma Reference Material.
Anal Chem
January 2025
Department of Biological Sciences, University of Alberta, Edmonton, Alberta T6G 2E9, Canada.
Article Synopsis
- Multiple analytical techniques were combined to analyze the NIST human plasma reference material SRM 1950, aiming to provide a validated list of metabolite concentration benchmarks for the metabolomics community.
- The study utilized four platforms—high-resolution NMR spectroscopy, direct injection tandem MS, liquid chromatography tandem MS, and inductively coupled plasma MS—resulting in accurate measurements for 728 unique metabolites and an additional 330 identified through literature mining.
- A comprehensive database (SRM1950-DB) with 1,058 metabolites, including information like structures and concentrations, is available online, representing the most thorough quantitative characterization of SRM 1950 to date.
Misdiagnosis and analysis of clinical characteristics in patients with giant cystic pheochromocytoma/paraganglioma.
Discov Oncol
December 2024
Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Introduction: Although giant cystic pheochromocytoma and paraganglioma (PPGL) are uncommon, they can be life-threatening when it occurs. Unfortunately, prior case reports have shown that giant cystic PPGLs are highly susceptible to diagnostic errors. Therefore, this study aimed to explore giant cystic PPGLs by comparing them with non-cystic PPGLs, defining the clinical features of the affected patients, and analyzing the characteristics of misdiagnosis and mistreatment associated with PPGLs.
View Article and Find Full Text PDFPheochromocytoma: an updated scoping review from clinical presentation to management and treatment.
Front Endocrinol (Lausanne)
December 2024
One Health Research Group, Universidad de las Americas, Quito, Ecuador.
Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors derived from chromaffin cells, with 80-85% originating in the adrenal medulla and 15-20% from extra-adrenal chromaffin tissues (paragangliomas). Approximately 30-40% of PPGLs have a hereditary component, making them one of the most genetically predisposed tumor types. Recent advances in genetic research have classified PPGLs into three molecular clusters: pseudohypoxia-related, kinase-signaling, and -signaling pathway variants.
View Article and Find Full Text PDFLC-ESI-MS/MS is a preferred method for detecting and identifying metabolites, including those that are unpredictable from the genome, especially in basal metazoans like Cnidaria, which diverged earlier than bilaterians and whose metabolism is poorly understood. However, the unexpected appearance of a "ghost peak" for dopamine, which exhibited the same m/z value and MS/MS product ion spectrum during an analysis of Nematostella vectensis, a model cnidarian, complicated its accurate identification. Understanding the mechanism by which "ghost peaks" appear is crucial to accurately identify the monoamine repertoire in early animals so as to avoid misassignments.
View Article and Find Full Text PDFBiochemical Sensors for Personalized Therapy in Parkinson's Disease: Where We Stand.
J Clin Med
December 2024
Operative Research Unit of Neurology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Álvaro del Portillo, 200, 00128 Rome, Italy.
Since its first introduction, levodopa has remained the cornerstone treatment for Parkinson's disease. However, as the disease advances, the therapeutic window for levodopa narrows, leading to motor complications like fluctuations and dyskinesias. Clinicians face challenges in optimizing daily therapeutic regimens, particularly in advanced stages, due to the lack of quantitative biomarkers for continuous motor monitoring.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!